GSK’s Exdensur wins EU nod for severe asthma
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
This transaction fundamentally strengthens Scinai's CDMO platform
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
Subscribe To Our Newsletter & Stay Updated